Amylin Uncovered: A Review on the Polypeptide Responsible for Type II Diabetes

Table 2

Amylin derivatives as potential inhibitors of cytotoxicty affected by full-length human amylin.

Amylin derivative	Position of 𝑁-methylated residue	Decrease in cytotoxicity	Cell line used	Reference
Amylin20--25		25%	RIN-1056A	[37]
Amylin24--29		0%	RIN-1056A	[37]
Amylin12--17		0%	RIN-1056A	[110]
Amylin15--20		0%	RIN-1056A	[110]
Amylin22--27	20 and 25	20%	RIN 5fm	[65]
Amylin1--37	24 and 26	50%	RIN 5fm	[103]
Amylin13--18		50%	RIN-1056A	[111]
Amylin20--25		50%	RIN-1056A	[111]
Amylin3--6		45%	RIN 5fm	[142]
Amylin3--6	3–5	0%	RIN 5fm	[142]
Amylin9--13		40%	RIN 5fm	[142]
Amylin9--13	9, 12, and 13	0%	RIN 5fm	[142]
Amylin15--20		20%	RIN 5fm	[142]
Amylin15--20	15–17 and 19	0%	RIN 5fm	[142]
Amylin22--27		40%	RIN 5fm	[142]
Amylin22--27	23–27	0%	RIN 5fm	[142]
Amylin29--34		50%	RIN 5fm	[142]
Amylin29--34	30 and 32–34	50%	RIN 5fm	[142]